Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07432633 · ClinicalTrials.gov registry record · Phase 1
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Blue Earth Diagnostics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT07432633 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Blue Earth Diagnostics. The registered enrollment target is 71 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07432633, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Blue Earth Diagnostics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Conditions Studied
Interventions
- DRUG [18F]FPyQCP
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07432633
The ClinicalTrials.gov registry entry for NCT07432633 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Blue Earth Diagnostics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]FPyQCP is the first listed.
NCT07432633 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07432633 about?
NCT07432633 is a clinical study titled "[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications". This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast ca...
What is the current status of trial NCT07432633?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2026-01-31. Estimated completion is 2028-01-31.
What conditions does trial NCT07432633 study?
This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Epithelial Ovarian Cancer, Invasive Lobular Breast Carcinoma.
What interventions are being tested in trial NCT07432633?
The interventions under investigation include: [18F]FPyQCP (DRUG).
Who is sponsoring clinical trial NCT07432633?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07432633 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.